When was Adaptimmune founded?

Adaptimmune was founded in 2008 and raised its 1st funding round 6 years after it was founded.

Where is Adaptimmune located?

Adaptimmune is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania.

Who is the current CEO of Adaptimmune?

Adrian Rawcliffe of Adaptimmune.

How many employees does Adaptimmune have?

As of Aug 31, 2026, the latest employee count at Adaptimmune is 127.

Is Adaptimmune a funded company?

Adaptimmune is a funded company, having raised a total of $104M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 25, 2014.

When was the latest funding round of Adaptimmune?

Adaptimmune's latest funding was a $***** Series A round on Sep 24, 2014, with participation from 12 investors.

What is the annual revenue of Adaptimmune?

Annual revenue of Adaptimmune is between $100M and $500M as on Dec 31, 2024

Where does Adaptimmune rank among its competitors?

Adaptimmune ranks 601st amongst 3404 active competitors, of which 1145 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Adaptimmune?

Adaptimmune's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Adaptimmune - 2026 Company Profile, Team, Funding, Competitors & Financials

Adaptimmune is a public company based in Philadelphia (United States), founded in 2008. It operates as a Developer of novel cancer immunotherapies to treat cancer and infectious disease. Adaptimmune has raised $104M in funding from New Enterprise Associates. The company has 3404 active competitors, including 1145 funded and 805 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of novel cancer immunotherapies to treat cancer and infectious disease. The therapies aim to utilize the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor proteins (TCRs) as a means of strengthening natural patient T cell responses. Its lead TCR programs are against esophageal, multiple myeloma, melanoma which the company is developing in collaboration with GSK.

Website: www.adaptimmune.com/
Social
Registered Address: Philadelphia, Pennsylvania

Key Metrics

Founded Year

2008

Location

Philadelphia, United States

Stage

Public

Total Funding

$104M in 2 rounds

Latest Funding Round

Series A, Sep 24, 2014, $*****

Investors

New Enterprise Associates & 18 more

Ranked

601^st among 3404 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2024

Employee Count

127 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3168 more

Exit Details

Public

View Adaptimmune's full profile

Adaptimmune is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Adaptimmune Limited CIN: 6456741 , United Kingdom, Active	Dec 18, 2007	-	-
ADAPTIMMUNE THERAPEUTICS PLC CIN: (44)1235430000 , Belgium, Active	Dec 31, 2007	$100M - $500M (As on Dec 31, 2024)	449 (As on Dec 31, 2023)	-
ADAPTIMMUNE LLC CIN: 274919915 , United States, Active	Dec 31, 1999	-	270 (As on Dec 31, 2024)	-

Adaptimmune got listed on May 06, 2015.

Click here to take a look at Adaptimmune's IPO in detail

Adaptimmune has raised a total funding of $104M over 2 rounds. Its first funding round was on Mar 25, 2014. Its latest funding round was a Series A round on Sep 24, 2014 for $*****. 12 investors participated in its latest round. Adaptimmune has 19 institutional investors.

Here is the list of recent funding rounds of Adaptimmune:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 24, 2014	4800759	Series A	5983070	5716250	1722034	7425949
Mar 25, 2014	2539136	Grant (prize money)	1979499	2280435	3455054	Mrc

Access funding benchmarks and valuations. Sign up today!

View details of Adaptimmune's funding rounds and investors

Adaptimmune's employee count trend

Adaptimmune has 127 employees as of Aug 26. Here is Adaptimmune's employee count trend over the years:

Uncover Adaptimmune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adaptimmune include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Adaptimmune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
601st	Adaptimmune 2008, Philadelphia (United States), Public	Developer of novel cancer immunotherapies to treat cancer and infectious disease	$104M	Foresite Capital, Avoro Capital & 17 others	50/100